comparemela.com

Latest Breaking News On - Capital markets investor relations - Page 1 : comparemela.com

Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) Programs at the SITC 37th Annual Meeting

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

United statesUnited kingdomDavid borahLukas stanczukKristin hurovJohanna lahdenrantaAnna lichtSarah suttonAlexandra rezvayaSociety for immunotherapy of cancerBicycle therapeuticsAnnual meetingLia luusBicycle toxin conjugateCancer research united kingdom centreCapital markets investor relations

Bicycle Therapeutics plc: Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

United kingdomDavid borahSarah suttonPiper sandlerBicycle therapeuticsLondon healthcare conferenceAnnual healthcare conferenceInvestors mediaBicycle toxin conjugateCancer research united kingdom centreCapital markets investor relations

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

-Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update; completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4 BT8009 clinical

United kingdomDavid borahGenentech immunoSarah suttonKevin leeExchange commissionChief executive officerTop line dose escalation resultsPhasei trialBicycle toxin conjugateInitial cohortsInitial expansion cohortsComplete thisPublications highlighting preclinical dataMolecular cancer therapeuticsMolecular cancer

Bicycle Therapeutics plc: Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

United kingdomDavid borahSarah suttonExchange commissionBicycle therapeuticsBicycle toxin conjugateMolecular cancerNicholas keenChief scientific officerMolecular cancer therapeuticsCancer research united kingdom centrePrivate securities litigation reform actQuarterly reportCapital markets investor relations

Bicycle Therapeutics plc: Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers; overall response rates of 22% (including one complete response) and 67%, respectively

United kingdomUnited statesDavid borahDominic smethurstSarah suttonKevin leeExchange commissionChief medical officerBicycle toxin conjugateChief executive officerResponse evaluation criteriaSolid tumorsBicycle therapeuticsInvestors mediaCancer research united kingdom centrePrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.